ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

ClinicalTrials.gov ID: NCT04102579

Public ClinicalTrials.gov record NCT04102579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Study identification

NCT ID
NCT04102579
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
128 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Valbenazine Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 12, 2019
Primary completion
Oct 14, 2021
Completion
Oct 25, 2021
Last update posted
Oct 10, 2023

2019 – 2021

United States locations

U.S. sites
42
U.S. states
28
U.S. cities
40
Facility City State ZIP Site status
Neurocrine Clinical Site Birmingham Alabama 35233
Neurocrine Clinical Site Little Rock Arkansas 72205
Neurocrine Clinical Site La Jolla California 92037
Neurocrine Clinical Site Sacramento California 95817
Neurocrine Clinical Site Aurora Colorado 80045
Neurocrine Clinical Site Englewood Colorado 80113
Neurocrine Clinical Site Washington D.C. District of Columbia 20007
Neurocrine Clinical Site Gainesville Florida 32608
Neurocrine Clinical Site Miami Florida 33136
Neurocrine Clinical Site Atlanta Georgia 30329
Neurocrine Clinical Site Chicago Illinois 60611
Neurocrine Clinical Site Chicago Illinois 60612
Neurocrine Clinical Site Indianapolis Indiana 46202
Neurocrine Clinical Site Iowa City Iowa 52242
Neurocrine Clinical Site Kansas City Kansas 66160
Neurocrine Clinical Site Wichita Kansas 67226
Neurocrine Clinical Site Louisville Kentucky 40202
Neurocrine Clinical Site New Orleans Louisiana 70121
Neurocrine Clinical Site Boston Massachusetts 02118
Neurocrine Clinical Site Boston Massachusetts 02215
Neurocrine Clinical Site Charlestown Massachusetts 02129
Neurocrine Clinical Site Ann Arbor Michigan 48109
Neurocrine Clinical Site West Bloomfield Michigan 48322
Neurocrine Clinical Site Omaha Nebraska 68198
Neurocrine Clinical Site Rochester New York 14618
Neurocrine Clinical Site Williamsville New York 14221
Neurocrine Clinical Site Durham North Carolina 27705
Neurocrine Clinical Site Fargo North Dakota 58103
Neurocrine Clinical Site Cleveland Ohio 44195
Neurocrine Clinical Site Columbus Ohio 43210
Neurocrine Clinical Site Toledo Ohio 43614
Neurocrine Clinical Site Pittsburgh Pennsylvania 15213
Neurocrine Clinical Site Charleston South Carolina 29425
Neurocrine Clinical Site Columbia South Carolina 29203
Neurocrine Clinical Site Greenville South Carolina 29615
Neurocrine Clinical Site Nashville Tennessee 37212
Neurocrine Clinical Site Houston Texas 77054
Neurocrine Clinical Site Salt Lake City Utah 84108
Neurocrine Clinical Site Burlington Vermont 05401
Neurocrine Clinical Site Charlottesville Virginia 22908
Neurocrine Clinical Site Seattle Washington 98195
Neurocrine Clinical Site Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04102579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 10, 2023 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04102579 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →